Clinical trials: Peripheral Nerve Injury (PNI)
Non-diabetic Painful Peripheral Polyneuropathy, Postherpetic Neuralgia (PHN)
A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment
This study is comparing the efficacy and tolerability of Qutenza with that of pregabalin in patients suffering from peripheral neuropathic pain.
- Conditions
- Non-diabetic Painful Peripheral Polyneuropathy, Postherpetic Neuralgia (PHN), Peripheral Nerve Injury (PNI)
- Trial name
- ELEVATE (NCT01713426)
- Testing
- Qutenza, Pregabalin
- Where
- 98 sites in Armenia, Austria and 20 more
- Volunteers
- 568 people
- Sponsor
- Astellas Pharma Europe Ltd.
Neuropathic Pain
Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults
The goal of this clinical trial is to learn if ASCT-83 is safe and well-tolerated and measure how ASCT-83 is absorbed, distributed, and eliminated from the body over time. The study will be conducted in healthy adults.
- Trial name
- NCT07363395
- Testing
- ASCT-83
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Alcamena Stem Cell Therapeutics
or Peripheral Nerve Injury (PNI), Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN)
Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch
The Summary of product characteristics (SmPC) for QUTENZA advises that topical anaesthetic is applied prior to the application of QUTENZA.
- Trial name
- LIFT (NCT01416116)
- Testing
- QUTENZA, Lidocaine, Tramadol
- Where
- 20 sites in Belgium, Czechia and 5 more
- Volunteers
- 122 people
- Sponsor
- Astellas Pharma Inc
Peripheral Nerve Injury Upper Limb, Peripheral Nerve Injury (PNI)
This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.
NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of severed nerves in patients between 18 and 80.
- Trial name
- NCT06616025
- Testing
- NTX-001 (PEG-Fusion)
- Where
- 25 sites in United States
- Volunteers
- 98 people
- Sponsor
- Neuraptive Therapeutics Inc.